Rafferty Asset Management, LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 387 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.

Quarter-by-quarter ownership
Rafferty Asset Management, LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$7,021,633
-21.5%
134,103
-39.0%
0.03%
-21.2%
Q1 2024$8,939,511
+7.6%
219,752
-2.2%
0.03%
-5.7%
Q4 2023$8,305,799
-6.0%
224,724
-2.8%
0.04%
-32.7%
Q3 2023$8,831,534
+0.1%
231,192
-5.5%
0.05%
+4.0%
Q2 2023$8,820,738
+41.3%
244,545
+49.6%
0.05%
+19.0%
Q1 2023$6,241,888
-22.5%
163,443
+15.4%
0.04%
-37.3%
Q4 2022$8,057,211
+21.8%
141,603
-15.4%
0.07%
-4.3%
Q3 2022$6,615,000
+72.5%
167,295
+92.0%
0.07%
+100.0%
Q2 2022$3,835,000
-37.6%
87,152
-43.4%
0.04%
-2.8%
Q1 2022$6,141,000
-0.1%
153,996
+0.8%
0.04%
+12.5%
Q4 2021$6,146,000
+99.9%
152,843
+102.3%
0.03%
+52.4%
Q3 2021$3,074,000
+11.1%
75,556
+23.9%
0.02%
+23.5%
Q2 2021$2,768,000
-11.6%
60,964
-18.8%
0.02%
-19.0%
Q1 2021$3,130,000
+222.7%
75,086
+230.6%
0.02%
+133.3%
Q4 2020$970,000
-49.7%
22,710
-69.0%
0.01%
-60.9%
Q3 2020$1,928,000
+71.8%
73,351
+75.3%
0.02%
+43.8%
Q2 2020$1,122,000
-22.4%
41,845
-48.7%
0.02%
-27.3%
Q4 2019$1,446,000
-40.5%
81,544
-47.9%
0.02%
-42.1%
Q3 2019$2,429,000
+4.5%
156,578
+15.7%
0.04%
-7.3%
Q2 2019$2,325,000
+36.8%
135,307
+28.2%
0.04%
+51.9%
Q1 2019$1,699,000105,5490.03%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Third Security, LLC 19,816,162$195,784,0009.33%
BB BIOTECH AG 5,846,564$57,764,0002.74%
QVT Financial LP 4,556,090$45,014,0002.44%
Parametrica Management Ltd 29,578$292,0002.21%
SECTORAL ASSET MANAGEMENT INC 4,389,682$43,370,0001.84%
Belmont Global Advisors, Inc. 257,000$2,539,0001.83%
HARVEY CAPITAL MANAGEMENT INC 394,550$3,898,0001.40%
Lombard Odier Asset Management (USA) Corp 1,350,000$13,338,0000.70%
IRIDIAN ASSET MANAGEMENT LLC/CT 6,199,685$61,253,0000.63%
Callan Capital, LLC 199,230$1,968,0000.53%
View complete list of HALOZYME THERAPEUTICS INC shareholders